49 min
Special Episode: Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer Inside the Lab
-
- Medicine
Although molecular testing offers promising opportunities for diagnosis and targeted treatment of cancers, prostate cancer has lagged behind other types of cancer. Recently, homologous recombination repair testing in prostate cancer has provided a means to achieving targeted treatments for patients as well as opening new avenues of collaboration between pathologists and oncologists.
On this episode of Inside the Lab, hosts Ms. Kelly Swails, MLS(ASCP), and Dr. Ali Brown, MD, FASCP are joined by Heather Cheng, a medical oncologist and associate professor of hematology and oncology at the University of Washington and Fred Hutchinson Cancer Center, and Colin Pritchard, molecular pathologist and professor of laboratory science and director of the Genetics and Solid Tumors Laboratory at the University of Washington Medical Center.
Our panelists discuss the current treatment landscape for prostate cancer and how HRR testing can improve patient outcomes in this context.
Topics Covered
An introduction to metastatic prostate cancer testing, and what types of tests are standard of care, and the rationale for targeting prostate cancer using PARPKey findings from recent phase III randomized clinical trialsStandards for optimal testing in prostate cancer, particularly concerning sample sources and the choice between next-generation sequencing (NGS) and polymerase chain reaction (PCR) methodscommon pitfalls or challenges in the arena of accurately reporting and interpreting findings from HRR testsPractical tips for optimal coordination among a multidisciplinary, cross-departmental team of healthcare providers and laboratory professionals when utilizing HRR testing in prostate cancer management.
Connect with ASCP
ASCP
ASCP on Facebook
ASCP on Instagram
ASCP on Twitter
Connect with Dr. Cheng
Dr. Cheng on LinkedIn
Connect with Dr. Pritchard
Dr. Pritchard
Connect with Ms. Swails & Dr. Brown
Ms. Swails on Twitter
Dr. Brown on Twitter
Resources
ASCP Membership 2024
Proposed FDA Regulation of Laboratory Developed Tests
Public Comment on the FDA’s Proposed Rule
Inside the Lab in the ASCP Store
Although molecular testing offers promising opportunities for diagnosis and targeted treatment of cancers, prostate cancer has lagged behind other types of cancer. Recently, homologous recombination repair testing in prostate cancer has provided a means to achieving targeted treatments for patients as well as opening new avenues of collaboration between pathologists and oncologists.
On this episode of Inside the Lab, hosts Ms. Kelly Swails, MLS(ASCP), and Dr. Ali Brown, MD, FASCP are joined by Heather Cheng, a medical oncologist and associate professor of hematology and oncology at the University of Washington and Fred Hutchinson Cancer Center, and Colin Pritchard, molecular pathologist and professor of laboratory science and director of the Genetics and Solid Tumors Laboratory at the University of Washington Medical Center.
Our panelists discuss the current treatment landscape for prostate cancer and how HRR testing can improve patient outcomes in this context.
Topics Covered
An introduction to metastatic prostate cancer testing, and what types of tests are standard of care, and the rationale for targeting prostate cancer using PARPKey findings from recent phase III randomized clinical trialsStandards for optimal testing in prostate cancer, particularly concerning sample sources and the choice between next-generation sequencing (NGS) and polymerase chain reaction (PCR) methodscommon pitfalls or challenges in the arena of accurately reporting and interpreting findings from HRR testsPractical tips for optimal coordination among a multidisciplinary, cross-departmental team of healthcare providers and laboratory professionals when utilizing HRR testing in prostate cancer management.
Connect with ASCP
ASCP
ASCP on Facebook
ASCP on Instagram
ASCP on Twitter
Connect with Dr. Cheng
Dr. Cheng on LinkedIn
Connect with Dr. Pritchard
Dr. Pritchard
Connect with Ms. Swails & Dr. Brown
Ms. Swails on Twitter
Dr. Brown on Twitter
Resources
ASCP Membership 2024
Proposed FDA Regulation of Laboratory Developed Tests
Public Comment on the FDA’s Proposed Rule
Inside the Lab in the ASCP Store
49 min